摘要
目的 探讨司美格鲁肽对肥胖2型糖尿病合并高脂血症患者脂糖代谢、血管内皮功能的影响分析。方法 前瞻性选取如皋市人民医院内分泌门诊2021年6月~2022年6月收治的肥胖2型糖尿病合并高脂血症患者108例,采用随机数字表法分为观察组(54例)和对照组(54例)。对照组给予口服二甲双胍治疗,观察组给予口服二甲双胍和皮下注射司美格鲁肽治疗,均治疗3个月。比较治疗前后两组患者的体格指标、糖代谢指标、脂代谢指标、血管内皮功能相关指标的差异以及不良反应发生情况。结果 治疗前,两组患者的相关检测指标差异无统计学意义(P> 0.05);治疗3月后,两组患者的体质量、体质量指数(BMI)、腰围、空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)均显著低于治疗前,且观察组低于对照组,差异有统计学意义(P <0.05);治疗3月后,两组患者ET-1较治疗前明显降低,NO水平较治疗前明显升高,且观察组ET-1水平更低,NO水平更高,差异有统计学意义(P <0.05)。两组不良反应总发生率差异无统计学意义(P> 0.05)。结论 司美格鲁肽用于治疗肥胖2型糖尿病合并高脂血症患者具有显著的减重效果,兼具控制血糖、血脂代谢、有效改善血管内皮功能,且安全性佳。
Objective To investigate the effect of Semeglutide on lipid metabolism,glucose metabolism and vascular endothelial function in obese type 2 diabetic patients with hyperlipidemia.Methods A total of 108 obese patients with type 2 diabetes mellitus complicated with hyperlipidemia admitted to the Endocrine Clinic of Rugao People's Hospital from June 2021 to June 2022 were selected as the research objects.They were divided into observation group(54 cases)and control group(54 cases)by random number table method.The observation group was treated with oral metformin,and the control group was treated with oral metformin and subcutaneous injection of semeiglutide for 3 months.The differences of physical indexes,glucose metabolism indexes,lipid metabolism indexes,vascular endothelial function related indexes and adverse reactions were compared between the two groups before and after treatment.Results Before treatment,there were no significant differences in the related parameters between the two groups(P>0.05);After 3 months of treatment,the BMI,waist circumference,FPG,2hPG,HbA1c,TC,LDL-C and TG of the two groups were significantly lower than those before treatment,and the indexes of the observation group were lower than those of the control group,and the differences were statistically significant(P<0.05);After 3 months of treatment,the level of ET-1 in the two groups was significantly lower than that before treatment(P<0.05),and the level of ET-1 in the observation group was lower than that before treatment(P<0.05),and the level of NO was significantly higher than that before treatment,and the level of NO in the observation group was higher than that before treatment(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Semeglutide has a significant weight loss effect in obese patients with type 2 diabetes mellitus and hyperlipidemia.It controls blood glucose and lipid metabolism,effectively improves vascular endothelial function,and demonstrates a
作者
章鸿雁
王芳
姚丽丽
Zhang Hongyan;Wang Fang;Yao Lili(Department of Endocrinology,Rugao People's Hospital,Nantong 226500,China)
出处
《中华保健医学杂志》
2023年第3期327-330,共4页
Chinese Journal of Health Care and Medicine
基金
南通市市级基础科学研究项目(JC2021120)。
关键词
司美格鲁肽
肥胖
2型糖尿病
高脂血症
脂糖代谢
血管内皮功能
Semeglutide
Obesity
Type 2 diabetes
Hyperlipidemia
Lipid and glucose metabolism
Vascular endothelial function
